For NSCLCa patients who are found to have N2 disease at time of surgery, what treatment volume do you use for PORT?

A post operative "surprise N2" should not be a common occurrence. These patients warrant systemic chemotherapy first. They are, of course at risk for local and systemic failure, and it was not until Drouiilard's observation from the ANITA trial that we were invited back. Subsequently, it is agreed ...

The current lung ART trial has good guidelines as prior studies have had significant variation amongst clinicians.

Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study.